▪ The offer period for the 15.6m warrants issued by Nexstim during the April capital raise has opened and will run through until 4 November, with a subscription price for each share of €0.115 or SEK1.24. ▪ The subscription price was based on the higher of a 25% discount to prevailing price (which was c €0.14) or €0.115. ▪ Subscription commitments for c €0.5m (4.1m warrants) have been made by Kaikarhenni Oy, Ossi Haapaniemi, Kalksten Properties Koy, and Capricorn Health-Tech Fund, together with members of the Board of Directors and management of Nexstim. ▪ The warrant offering is fully underwritten, guaranteeing that Nexstim will raise €1.79m (gross) from the warrant offering. There is an agreement with a limited number of existing shareholders and external investors, who will purchase any of the 15.6m shares allocated to the warrant offering that have not being bought, i.e. up to 11.5m shares after the subscription commitments. ▪ The capital raise will, subject to the approval of an EGM, be supplemented by a directed share issue at €0.115/share of up to 9.8m new shares to the group of investors underwriting the warrant offering. This could result in an additional €1.12m being raised, before expenses.
22 Oct 2019
Warrants to be topped up with share placement
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Warrants to be topped up with share placement
▪ The offer period for the 15.6m warrants issued by Nexstim during the April capital raise has opened and will run through until 4 November, with a subscription price for each share of €0.115 or SEK1.24. ▪ The subscription price was based on the higher of a 25% discount to prevailing price (which was c €0.14) or €0.115. ▪ Subscription commitments for c €0.5m (4.1m warrants) have been made by Kaikarhenni Oy, Ossi Haapaniemi, Kalksten Properties Koy, and Capricorn Health-Tech Fund, together with members of the Board of Directors and management of Nexstim. ▪ The warrant offering is fully underwritten, guaranteeing that Nexstim will raise €1.79m (gross) from the warrant offering. There is an agreement with a limited number of existing shareholders and external investors, who will purchase any of the 15.6m shares allocated to the warrant offering that have not being bought, i.e. up to 11.5m shares after the subscription commitments. ▪ The capital raise will, subject to the approval of an EGM, be supplemented by a directed share issue at €0.115/share of up to 9.8m new shares to the group of investors underwriting the warrant offering. This could result in an additional €1.12m being raised, before expenses.